CAO Guy Wendy buys 1,748 shares of struggling biotech PCSA at market lows, adding to holdings amid deep losses.
Chief Administrative Officer Guy Wendy purchased nearly 1,750 shares of Processa Pharmaceuticals at current market levels, representing a meaningful increase to his holdings and signaling confidence in the stock's long-term value. This is noteworthy because the purchase occurs while the company is unprofitable with substantial operating losses and minimal revenue, fundamentals that have deteriorated sharply year-over-year. The stock is trading well below its recent highs, suggesting Wendy sees asymmetric risk-reward at depressed valuations. As a C-suite officer with direct insight into company operations and strategy, his decision to deploy personal capital during a period of financial stress—rather than waiting for turnaround proof—suggests conviction that the business trajectory or assets have value not yet reflected in the market price.
CAO Guy Wendy buys 1,583 shares of PCSA at $2.97; 5 other insiders also bought in past 14 days (cluster pattern).
Guy Wendy, Chief Administrative Officer, purchased 1,583 shares at $2.97 on 2026-04-15, increasing her holdings by +50.9% to 4,693 shares. This transaction is part of a cluster pattern in which 5 other insiders also bought within the past 14 days, suggesting coordinated confidence at current valuations. However, context is mixed: the stock trades at $3.10 (current price), down -74.1% from its 52-week high of $11.97, and the company posted zero revenue in the latest quarter with a net loss of $-3.4M and a market cap of $8.2M. While multiple insider purchases can indicate management belief in value, the severe valuation pressure and operational losses in an unprofitable biotech warrant careful scrutiny of the motivations underlying this cluster activity.
CAO Guy Wendy buys 1,854 shares at $2.54; 9 insiders bought within 14 days as PCSA stock trades -78.3% from 52-week high
Guy Wendy, Chief Administrative Officer of Processa Pharmaceuticals, purchased 1,854 shares at $2.54 on 2026-03-31, increasing holdings by 147.6% to 3,110 shares post-transaction. This buy coincides with a broader cluster pattern: 8 other insiders also purchased within the past 14 days, indicating coordinated accumulation at depressed valuations. The stock is trading at $2.60, representing a -78.3% decline from its 52-week high of $11.97, though it has recovered +14.0% over the past 30 days. The company remains deeply unprofitable with net income of $-3.4M on zero revenue in the latest quarter, and carries a modest market capitalization of $6.9M. The confluence of multi-insider buying during a severe drawdown from peak valuations warrants attention to what these insiders perceive in the company's trajectory.
